PDYN

PDYN encodes preprodynorphin, a brain-restricted precursor that is proteolytically processed into multiple dynorphin opioid peptides that signal primarily through κ-opioid receptors, with defined roles in stress signaling, feeding regulation, and neonatal suckling behavior (PMID:10657497, PMID:36768626, PMID:27260403). PDYN transcription is controlled by a complex cis-regulatory architecture—including a 68-bp repeat, microsatellites, and 3′UTR haplotypes that modulate expression in a brain-region- and sex-dependent manner—and is repressed by the transcription factors REST (itself regulated by miR-9) and DREAM, whose SIRT1-dependent stabilization suppresses PDYN-mediated neurotoxicity (PMID:19910384, PMID:18923396, PMID:25220237, PMID:30503815). SCA23-causing missense mutations in the dynorphin A-coding region disrupt the peptide's N-terminal α-helix, reduce κ-opioid receptor affinity, and generate degradation-resistant aggregation-prone peptides that redirect signaling toward NMDA-receptor-mediated cerebellar excitotoxicity (PMID:27260403, PMID:23471613). In the brain, dynorphin peptides act upstream of stress-induced JNK1/2–FADD signaling and suppress microglial pyroptosis via inhibition of the PI3K/AKT/mTOR pathway (PMID:36768626, PMID:41544679).

1. 1999 Medium

   Establishing that Pdyn encodes a brain-restricted preprodynorphin precursor with conserved dynorphin peptide products and tightly regulated developmental onset answered the basic question of when and where PDYN is expressed.

   Evidence RT-PCR across mouse developmental stages and adult tissues; gene sequencing

   PMID:10657497

   Open questions at the time

   • No functional consequence of developmental timing established
   • Expression profiling limited to RT-PCR without protein-level confirmation
   • Human tissue expression pattern not directly characterized
2. 2008 Medium

   Identifying a 3′UTR haplotype that reduces PDYN mRNA in reward-relevant brain regions established that common cis-regulatory variation directly modulates prodynorphin expression in vivo, linking regulatory genetics to addiction-relevant phenotypes.

   Evidence Allele-specific expression by SNaPshot assay in heterozygous postmortem human brains; association with cocaine dependence

   PMID:18923396

   Open questions at the time

   • Mechanism by which 3′UTR haplotype reduces mRNA (stability vs. transcription) not resolved
   • Causal role in cocaine dependence not established by expression data alone
3. 2009 Medium

   Demonstrating that five 5′ cis-regulatory polymorphisms interact epistatically and in a brain-region- and sex-dependent manner to control PDYN transcript levels revealed an unexpectedly complex regulatory architecture for a neuropeptide gene.

   Evidence Parallel in vivo allele-specific expression in human brain and in vitro reporter assays

   PMID:19910384

   Open questions at the time

   • Trans-acting factors mediating region- and sex-specific effects not identified
   • Epigenetic contributions not examined
4. 2013 Medium

   Showing that SCA23-associated PDYN missense mutations quantitatively alter dynorphin peptide output—either increasing or abolishing it—provided the first direct link between PDYN coding variants and a cerebellar ataxia, answering whether SCA23 mutations act at the level of precursor processing.

   Evidence Peptide production assays using patient-derived PDYN variants

   PMID:23471613

   Open questions at the time

   • In vivo peptide levels in patient cerebellum not measured
   • Whether gain or loss of dynorphin is the primary pathogenic driver remained unclear
5. 2014 Medium

   Establishing that REST binds and represses the PDYN locus, with miR-9-mediated REST downregulation releasing PDYN expression in the adult brain, identified a specific transcription factor–microRNA axis governing PDYN transcription.

   Evidence ChIP for REST at PDYN locus; siRNA and dominant-negative REST interference; RT-PCR in SH-SY5Y cells and postmortem human brain

   PMID:25220237

   Open questions at the time

   • miR-9 effect on REST at the PDYN locus shown only by correlation, not by direct manipulation
   • Whether REST-PDYN axis operates in vivo in specific neuronal subtypes not tested
6. 2016 High

   Resolving the molecular mechanism of SCA23 pathogenicity: disease-causing mutations disrupt the dynorphin A α-helix, reduce κ-opioid receptor binding, and generate stable, insoluble peptides that cause NMDA-receptor-dependent excitotoxicity—establishing a gain-of-toxic-function mechanism distinct from simple loss of opioid signaling.

   Evidence Molecular dynamics simulations; κ-opioid receptor binding assays; peptide stability/solubility measurements; primary cerebellar neuron toxicity assays with NMDA receptor antagonists

   PMID:27260403

   Open questions at the time

   • Whether NMDA receptor interaction is direct or mediated by an intermediate not determined
   • In vivo cerebellar pathology from mutant dynorphin not demonstrated in animal models
7. 2018 Medium

   Positioning PDYN as a downstream effector of the SIRT1–DREAM signaling axis in motor neuron-like cells established that DREAM degradation derepresses PDYN, and that PDYN upregulation itself is sufficient to drive neurotoxicity.

   Evidence Co-immunoprecipitation for DREAM acetylation/ubiquitination; siRNA knockdown of PDYN; cell viability assays in SOD1-G93A neuronal cells

   PMID:30503815

   Open questions at the time

   • Whether DREAM directly binds the PDYN promoter not shown by direct ChIP in this system
   • Relevance to in vivo ALS pathology not demonstrated
8. 2023 Medium

   Using PDYN knockout mice to show that dynorphin peptides are required for stress-induced JNK1/2 and FADD activation—but dispensable for ERK1/2 and Akt-mTOR stress responses—placed PDYN upstream of a selective branch of stress-responsive MAPK signaling in the brain.

   Evidence Western blot of phospho-MAPKs and FADD in cortex/thalamus of PDYN-KO vs. WT mice under acute and chronic stress paradigms

   PMID:36768626

   Open questions at the time

   • Whether dynorphin activates JNK1/2-FADD through κ-opioid receptor or directly is not resolved
   • Cell-type specificity of the signaling effect within cortex/thalamus unknown
9. 2025 Medium

   Demonstrating that PDYN overexpression suppresses microglial pyroptosis and neuroinflammation via PI3K/AKT/mTOR pathway inhibition extended dynorphin's intracellular signaling role to neuroinflammatory contexts and identified a second downstream pathway through which PDYN-derived peptides exert neuroprotection.

   Evidence CLP sepsis mouse model; pharmacological PI3K activator rescue; in vitro LPS-treated microglia

   PMID:41544679

   Open questions at the time

   • Which processed dynorphin peptide mediates the anti-pyroptotic effect is unknown
   • Whether the effect is κ-opioid receptor-dependent not tested

• Key unresolved questions include: which specific dynorphin peptide product mediates each downstream signaling effect (JNK1/2-FADD vs. PI3K/AKT/mTOR suppression), whether SCA23 mutant dynorphins interact directly with NMDA receptors, and how the complex cis-regulatory and trans-factor (REST, DREAM) landscape integrates in vivo across neuronal subtypes and brain regions.
• No structural model of mutant dynorphin–NMDA receptor interaction exists
• In vivo animal model of SCA23 from PDYN mutations not yet generated
• Cell-type-resolved mapping of PDYN regulatory inputs (REST, DREAM, cis-variants) lacking